



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/777,554	02/06/2001	Barbara Scott	BBI-6077CP	8200
959	7590	03/31/2004	EXAMINER	
LAHIVE & COCKFIELD, LLP. 28 STATE STREET BOSTON, MA 02109			SHIAO, REI TSANG	
			ART UNIT	PAPER NUMBER
			1626	

DATE MAILED: 03/31/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

09/777,554

Applicant(s)

SCOTT ET AL.

Examiner

Robert Shiao

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on RCE of 0977,554, filed 2/09, 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-60 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-60 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.


### **DETAILED ACTION**

1. This application claims benefit of the provisional application: 60/180,841 with a filing date 02/07, 2000.
2. Amendment of claims 58-60 in Paper No. 0204, dated February 9, 2004, is acknowledged. A telephone call was made to Gayle B. O'Brien on March 22, 2004, to request an oral election to the restriction requirement, but did not result in an election being made. Claims 1-60 are pending in the application. The previous restriction requirement, dated July 30, 2002, has been modified as follows.

### ***Election/Restriction***



3. The Markush group set forth in the claims includes both independent and distinct inventions, and patentably distinct compounds (or species) within each invention. However, this application discloses and claims a plurality of patentably distinct inventions far too numerous to list individually. Moreover, each of these inventions contains a plurality of patentably distinct compounds, also far too numerous to list individually. For these reasons provided below, restriction to one of the following Groups is required under 35 U.S.C. 121, wherein an Group is a set of patentably distinct inventions of a broad statutory category (e.g. Compounds, Methods of Use, Methods of Making, etc.):
  - I. Claims 1-22, and 38-58, in part, drawn to compounds/compositions, wherein the variable Q represents hydrogen thereof; the variables Q and X<sup>1</sup>, and two nitrogen

Art Unit: 1626



atoms, are not together to form the ring; the variable Y represents O or S; the variable W does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable W is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof; the variable  $X^1$  does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable  $X^1$  is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof, the variables  $R^1$ ,  $R^2$ , and  $R^3$  independently do not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, the variables  $R^1$ ,  $R^2$ , and  $R^3$  independently are not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety; the variables  $R^1$  and W together with their attached carbons do not form a 5- or 6-membered heterocyclcyl ring thereof;  $R^3$  and  $X^1$  together with the


nitrogen atom do not form a heterocycle ring




thereof; classified in classes 514/548, numerous subclasses. If this group is elected, applicants are requested to elect a single species for the search purpose.

Art Unit: 1626

- II. Claims 1-22, and 38-58, in part, drawn to compounds/compositions, wherein the variable Q represents hydrogen thereof; the variables Q and X<sup>1</sup>, and two nitrogen




atoms, are not together to form the ring; the variable Y represents O or S; the variable W does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable W is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof; the variable X<sup>1</sup> does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable X<sup>1</sup> is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof; the variables R<sup>1</sup> and R<sup>2</sup> independently does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, variables R<sup>1</sup> and R<sup>2</sup> independently are not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety; the variable R<sup>3</sup> represents heterocycle morpholine or piperazine thereof; the variables R<sup>1</sup> and W together with their attached carbons do not form a 5- or 6-membered heterocyclyl ring thereof; R<sup>3</sup> and X<sup>1</sup> together with the nitrogen atom




do not form a heterocycle ring, or thereof; classified in classes 514/544, numerous subclasses. If this group is elected, applicants are requested to elect a single species for the search purpose.

Art Unit: 1626

III. Claims 1-22, and 38-58, in part, drawn to compounds/compositions, wherein the variable Q represents hydrogen thereof; the variables Q and  $X^1$ , and two nitrogen




atoms, are not together to form the ring; the variable Y represents O or S; the variable W does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable W is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof; the variable  $X^1$  does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable  $X^1$  is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof, the variables  $R^1$  and  $R^2$  independently does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, the variables  $R^1$  and  $R^2$  independently are not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety; the variable  $R^3$  represents heterocycle piperidine or pyridine thereof; the variables  $R^1$  and W together with their attached carbons do not form a 5- or 6-membered heterocyclyl ring thereof;  $R^3$  and  $X^1$  together with the nitrogen atom do not form




a heterocycle ring , or thereof; classified in classes 514/546, numerous subclasses. If this group is elected, applicants are requested to elect a single species for the search purpose.

Art Unit: 1626

- IV. Claims 1-22, and 38-58, in part, drawn to compounds/compositions, wherein the variable Q represents hydrogen thereof; the variables Q and X<sup>1</sup>, and two nitrogen



atoms, are not together to form the ring; the variable Y represents O or S; the variable W does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable W is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof; the variable X<sup>1</sup> does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, and the variable X<sup>1</sup> is not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety thereof, the variables R<sup>1</sup> and R<sup>2</sup> independently does not represent heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety, the variables R<sup>1</sup> and R<sup>2</sup> independently are not substituted with heteroaryl or heterocycle (i.e., morpholine, piperidine, etc) moiety; the variable R<sup>3</sup> represents heterocycle imidazole thereof; the variables R<sup>1</sup> and W together with their attached carbons do not form a 5- or 6-membered heterocyclyl ring thereof, R<sup>3</sup> and X<sup>1</sup> together with the nitrogen atom do not form



a heterocycle ring , or thereof; classified in classes 514/548, numerous subclasses. If this group is elected, applicants are requested to elect a single species for the search purpose.

Art Unit: 1626

- V. Claims 1-22, and 38-58, in part, drawn to compounds/compositions of a compound of formula (I), receiving compounds of formula (I) not encompassed in Groups I-IV, classified in classes 514/544/546/548, numerous subclasses. This group is subject to further restriction if it is elected. If this group is elected, applicants are requested to elect a single species for the search purpose.
- VI. Claims 23-28, drawn to methods of use (i.e., protein kinase inhibition) of a compound of formula (I), classified in classes 514, numerous subclasses. If this group is elected, applicants are requested to elect a single species for the search purpose.
- VII. Claims 29-37, and 59-60 drawn to methods of use (i.e., treating ulcer or tumors) of a compound of formula (I), classified in classes 514, numerous subclasses. If this group is elected, applicants are requested to elect a single species for the search purpose.

If one of Group VI-VII is elected, then election of one of the following methods of use is required:

- A. Method of treating ulcer
- B. Method of treating ocular neovascular disease
- C. Method of treating fibrosarcoma
- D. Method of treating diabetes

Art Unit: 1626

An election of any one of Groups I-VII is required. Where an election of any one of Groups I-VII is made, an election of a single species is further required including an exact definition of each substitution on the base molecule (Formula I), wherein a single member at each substituent group or moiety is selected. For example, if a base molecule has substituent groups  $R^1$  or  $R^2$ , wherein  $R^1$  and  $R^2$  are independently recited to be any one of hydrogen, alkyl, cycloalkyl, etc., then applicant must select a single substituent of  $R^1$ , for example hydrogen, and each subsequent variable position. Should applicant traverse on the ground that the compounds are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the compounds to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C 103(a) of the other.

All compounds falling outside the class(es) and subclass(es) of the selected compound and any other subclass encompassed by the election above will be directed to nonelected subject matter and will be withdrawn from consideration under 35 U.S.C. 121 and 37 C.F.R. 1.142(b). Applicant may reserve the right to file divisional applications on the remaining subject matter. The provisions of 35 U.S.C. 121 apply with regard to double patenting covering divisional applications.

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventors must be amended in compliance with 37C.F.R. 1.48(b) if one of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1626

application. Any amendment of inventorship must be accompanied by a petition under 37 C.F.R. 1.48(b) and by the fee required under 37CFR 1.17(i).

If desired upon election of a single compound, applicants can review the claims and disclosure to determine the scope of the invention and can **set forth** a group of compounds which are so similar within the same inventive concept and reduction to practice. Markush claims must be provided with support in the disclosure for each member of the Markush group. See MPEP 608.01(p). Applicant should exercise caution in making a selection of a single member for each substituent group on the base molecule to be consistent with the written description.

***Rationale Establishing Patentable Distinctiveness Within Each Group***

Each Invention Set listed above is directed to or involves the use or making of compounds which are recognized in the art as being distinct from one another because of their diverse chemical structure, their different chemical properties, modes of action, different effects and reactive conditions (MPEP 806.04, MPEP 808.01). Additionally, the level of skill in the art is not such that one invention would be obvious over either of the other inventions, i.e. they are patentable over each other. Chemical structures which are similar are presumed to function similarly, whereas chemical structures that are not similar are not presumed to function similarly. The presumption even for similar chemical structures though is not irrebuttable, but may be overcome by scientific reasoning or evidence showing that the structure of the prior art would not have been expected to function as the structure of the claimed invention. Note that in accordance with the holdings of Application of Papesch, 50 CCPA 1084, 315 F.2d 381, 137 USPQ

Art Unit: 1626

43 (CCPA 1963) and In re Laly, 223 USPQ 1257 (Fed. Cir. 1984), chemical structures are patentably distinct where the structures are either not structurally similar, or the prior art fails to suggest a function of a claimed compound would have been expected from a similar structure.

***The above Groups represent general areas wherein the inventions are independent and distinct, each from the other because of the following reasons:***

Groups I-VII are independent and distinct compound/composition, because heterocycle (i.e., morpholine, piperidine, piperazine, etc.) of formula (I), each group differ in elements, bonding arrangement and chemical property to such an extend that a reference anticipating compounds of any one group would not render another group obvious.

Each of different methods of use inventions set forth in Groups VI and Group VII are unrelated. Invention are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP 806.04, MPEP 808.01). Methods of use are unrelated if one of three difference are found between them. These are 1) the population being treated, 2) the material being used, and 3) the methodology for treatment. If any one or more of this difference exist and are patently distinct, then the methods are unrelated. In the instant case, the different methods of use inventions are unrelated because patient population treated for each method is divergent. For example, a method of treating diabetes presumes that the patients being treated have diabetes, while a method of treating cancer presumes that the patients have cancer.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

In addition, because of the plethora of classes and subclasses in each of the Groups, a serious burden is imposed on the examiner to perform a complete search of the defined areas. Therefore, because of the reasons given above, the restriction set forth is proper and not to restrict would impose a serious burden in the examination of this application.

#### ***Advisory of Rejoinder***

**4.** The following is a recitation of M.P.E.P. §821.04, Rejoinder:

Where product and process claims drawn to independent and distinct inventions are presented in the same application, applicant may be called upon under 35 U.S.C. 121 to elect claims to either the product or process. See MPEP § 806.05(f) and § 806.05(h). The claims to the nonelected invention will be withdrawn from further consideration under 37 CFR 1.142. See MPEP § 809.02 (c) and § 821 through § 821.03. However, if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claim will be rejoined.

Where product and process claims are presented in a single application and that application qualifies under the transitional restriction practice pursuant to 37 CFR 1.129(b), applicant may either (1) elect the invention to be searched and examined and pay the fee set forth in 37 CFR 1.17(s) and have the additional inventions searched and examined under 37 CFR 1.129(b)(2), or (2) elect the invention to be searched and examined and not pay the additional fee (37 CFR 1.129(b)(3)). Where no additional fee is paid, if the elected invention is directed to the product and the claims directed to the product are subsequently found patentable, process claims which either depend from or include all the limitations of the allowable product will be rejoined. If applicant chooses to pay the fees to have the additional inventions searched and examined pursuant to 37 CFR 1.129(b)(2), even if the product is found allowable, applicant would not be

Art Unit: 1626

entitled to a refund of the fees paid under 37 CFR 1.129(b) by arguing that the process claims could have been rejoined. 37 CFR 1.26 states that "money paid by actual mistake or in excess will be refunded, but a mere change of purpose after the payment of money...will not entitle a party to demand such a return..." The fees paid under 37 CFR 1.129(b) were not paid by actual mistake nor paid in excess, therefore, applicant would not be entitled to a refund.

In the event of rejoinder, the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104 - 1.106. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. If the application containing the rejoined claims is not in condition for allowance, the subsequent Office action may be made final, or, if the application was already under final rejection, the next Office action may be an advisory action.

The following is a recitation from paragraph five, "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C.

§103(b)" (1184 TMOG 86(March 26, 1996)):

"However, in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim **depends from or otherwise includes all the limitations of** an allowed product claim. Withdrawn process claims not commensurate in scope with an allowed product claim will not be rejoined." (emphasis added)

Therefore, in accordance with M.P.E.P. §821.04 and *In re Ochiai*, 71 F.3d 1565, 37 USPQ 1127 (Fed. Cir. 1995), rejoinder of product claims with process claims commensurate in scope with the allowed product claims will occur following a finding that the product claims are allowable. Until, such time, a restriction between product claims and process claims is deemed proper. Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution to maintain either dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**


Art Unit: 1626

***Telephone Inquiry***


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Joseph K. McKane  
Supervisory Patent Examiner  
Art Unit 1626



Robert Shiao, Ph.D.  
Patent Examiner  
Art Unit 1626

March 26, 2004